ATE506961T1 - CCN3 PROTEINS FOR THE TREATMENT AND DIAGNOSIS OF KIDNEY DISEASES - Google Patents
CCN3 PROTEINS FOR THE TREATMENT AND DIAGNOSIS OF KIDNEY DISEASESInfo
- Publication number
- ATE506961T1 ATE506961T1 AT06717966T AT06717966T ATE506961T1 AT E506961 T1 ATE506961 T1 AT E506961T1 AT 06717966 T AT06717966 T AT 06717966T AT 06717966 T AT06717966 T AT 06717966T AT E506961 T1 ATE506961 T1 AT E506961T1
- Authority
- AT
- Austria
- Prior art keywords
- ccn3
- diseases
- treatment
- protein
- diagnosis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention discloses a role of CCN3 in diseases associated with the overexpression of CCN2, which include but are not limited to kidney disease, fibrosis, and cancer. The full length CCN3 protein or fragments thereof or isoforms (or combinations) of CCN3 are involved in these diseases. The isolated and purified CCN3 protein or its fragments or isoforms (or combinations) of CCN3 can be potentially used in the treatment or prevention of these diseases by regulating the expression and/or activity of the CCN2 protein. The level of CCN3 in tissue or body fluids can also be used to predict, diagnose and/or follow the progression of diseases as well as to determine the effectiveness of therapeutic intervention.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64272805P | 2005-01-10 | 2005-01-10 | |
PCT/US2006/000833 WO2006074452A2 (en) | 2005-01-10 | 2006-01-10 | Regulation of ccn2 by ccn3 and its therapeutic and diagnostic potential in fibrosis, sclerosis and other diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE506961T1 true ATE506961T1 (en) | 2011-05-15 |
Family
ID=36648253
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06717966T ATE506961T1 (en) | 2005-01-10 | 2006-01-10 | CCN3 PROTEINS FOR THE TREATMENT AND DIAGNOSIS OF KIDNEY DISEASES |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1841316B1 (en) |
JP (1) | JP4834677B2 (en) |
AT (1) | ATE506961T1 (en) |
AU (1) | AU2006203851B8 (en) |
CA (1) | CA2597794A1 (en) |
DE (1) | DE602006021534D1 (en) |
DK (1) | DK1841316T3 (en) |
ES (1) | ES2395260T3 (en) |
PL (1) | PL1841316T3 (en) |
WO (1) | WO2006074452A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0618748D0 (en) * | 2006-09-22 | 2006-11-01 | Univ Belfast | Peptide |
EP2767833A3 (en) * | 2008-10-21 | 2014-12-17 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
US9114112B2 (en) * | 2010-04-02 | 2015-08-25 | Rosalind Franklin University Of Medicine And Science | CCN3 and CCN3 peptides and analogs thereof for therapeutic uses |
US8518395B2 (en) * | 2010-04-02 | 2013-08-27 | Rosalind Franklin University Of Medicine And Science | CCN3 peptides and analogs thereof for therapeutic use |
WO2011134063A1 (en) * | 2010-04-26 | 2011-11-03 | UNIVERSITé LAVAL | Ccn3 and uses thereof against metabolic syndrome- associated disorders |
US10028906B2 (en) | 2016-03-22 | 2018-07-24 | Rosalind Franklin University Of Medicine And Science | Method and kit for treating a solid tumor and associated desmoplasia |
EP3711772A1 (en) * | 2019-03-20 | 2020-09-23 | Oslo Universitetssykehus HF | Recombinant proteins and fusion proteins |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040009940A1 (en) * | 2000-10-20 | 2004-01-15 | Coleman Michael E. | Gene delivery formulations and methods for treatment of ischemic conditions |
FR2825928B1 (en) * | 2001-06-18 | 2004-04-02 | Ecole Norm Superieure Cachan | PHARMACEUTICAL COMPOSITION FOR DIAGNOSING, PREVENTING OR TREATING TUMOR PATHOLOGY, COMPRISING AN AGENT MODULATING POLYMERIZATION OF ACTIN |
EP1382347A1 (en) * | 2002-07-17 | 2004-01-21 | UNIVERSITE PARIS 7 - Denis DIDEROT | Use of CCN protein family members for the treatment of disorder associated to an altered calcium and/or sodium flux |
EP1608970A4 (en) * | 2003-03-31 | 2006-06-14 | Munin Corp | Ccn3 compositions and methods |
WO2006036962A2 (en) * | 2004-09-28 | 2006-04-06 | Lau Lester F | Compositions and methods for modulating tissue regeneration and chemotactic responses |
-
2006
- 2006-01-10 AU AU2006203851A patent/AU2006203851B8/en not_active Ceased
- 2006-01-10 CA CA002597794A patent/CA2597794A1/en not_active Abandoned
- 2006-01-10 EP EP06717966A patent/EP1841316B1/en active Active
- 2006-01-10 AT AT06717966T patent/ATE506961T1/en active
- 2006-01-10 DE DE602006021534T patent/DE602006021534D1/en active Active
- 2006-01-10 JP JP2007550562A patent/JP4834677B2/en not_active Expired - Fee Related
- 2006-01-10 WO PCT/US2006/000833 patent/WO2006074452A2/en active Application Filing
- 2006-01-10 ES ES06717966T patent/ES2395260T3/en active Active
- 2006-01-10 PL PL06717966T patent/PL1841316T3/en unknown
- 2006-01-10 DK DK06717966.3T patent/DK1841316T3/en active
Also Published As
Publication number | Publication date |
---|---|
EP1841316A2 (en) | 2007-10-10 |
AU2006203851B8 (en) | 2012-11-15 |
WO2006074452A3 (en) | 2006-11-16 |
AU2006203851A1 (en) | 2006-07-13 |
DK1841316T3 (en) | 2011-08-08 |
AU2006203851B2 (en) | 2012-04-12 |
ES2395260T3 (en) | 2013-02-11 |
PL1841316T3 (en) | 2011-09-30 |
EP1841316B1 (en) | 2011-04-27 |
EP1841316A4 (en) | 2008-07-09 |
CA2597794A1 (en) | 2006-07-13 |
DE602006021534D1 (en) | 2011-06-09 |
WO2006074452A2 (en) | 2006-07-13 |
JP4834677B2 (en) | 2011-12-14 |
JP2008526890A (en) | 2008-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RS20150135A1 (en) | Treatment with anti-vegf antibodies | |
ATE506961T1 (en) | CCN3 PROTEINS FOR THE TREATMENT AND DIAGNOSIS OF KIDNEY DISEASES | |
EA200700886A1 (en) | CONNECTION OF TIADIAZOLE AND ITS APPLICATION | |
EA200971053A1 (en) | METHODS OF TREATMENT OF THE LEAD ULCERS | |
EA200700333A1 (en) | THERAPEUTIC APPLICATIONS OF RTP801 INHIBITORS | |
DE602004014117D1 (en) | THIAZOLE FOR USE AS INHIBITORS OF PROTEIN KINASES | |
PH12015500297A1 (en) | Adoptosis-inducing agents for the treatment of cancer and immune and automoimmune disease | |
EA201070636A1 (en) | INHIBITION OF THE PROTECTOR PROTEIN, STIMULATING MACROPHAGE (RON), AND METHODS OF ITS TREATMENT | |
DE502005010615D1 (en) | MEDICINE FOR THE TREATMENT OF INFLAMMATORY DISEASES | |
EA200900177A1 (en) | SUBSTITUTED ACYLANILIDES AND METHODS OF THEIR APPLICATION | |
EA201000644A1 (en) | ANTIBODIES FOR THE TREATMENT AND PREVENTION OF THE ALZGEIMER'S DISEASE AND THEIR APPLICATION | |
EA200600414A1 (en) | BORONIC ACID DERIVATIVES (OPTIONS), INTERMEDIATE CONNECTIONS, METHODS OF OBTAINING THEM, COMPOSITION FOR INHIBITING NF-kB ACTIVITY AND PROGRAM DEGRADATION AND METHODS OF DISEASE TREATMENT (OPTIONS) | |
TW200800976A (en) | New compounds for the treatment of neurological, psychiatric or pain disorders | |
MY140132A (en) | Thiazolidin-4-one derivatives for use in the treatment of anemias | |
EA200601212A1 (en) | PHOSPHODESTERASE INHIBITORS, OBTAINING AND THEIR THERAPEUTIC APPLICATION | |
EA200600921A1 (en) | METHODS AND COMPOSITIONS WITH THE USE OF TALIDOMIDE FOR THE TREATMENT AND MANAGEMENT OF CANCER AND OTHER DISEASES | |
ATE510536T1 (en) | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF REACTIVE TISSUE DISEASES | |
ATE472998T1 (en) | CATIONIC LIPOSOMAL PREPARATIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS | |
EA200801425A1 (en) | DIAZEPINONY | |
MY179250A (en) | Protein biomarkers for soft tissue disease diagnosis and as therapeutic targets for oral care intervention | |
WO2008090332A3 (en) | Factor h polymorphisms in the diagnosis and therapy of inflammatory diseases such as age-related macular degeneration | |
DK1596879T3 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
TW200603791A (en) | Compounds and compositions as cathepsin S inhibitors | |
TNSN06147A1 (en) | Use of cathepsin k inhibitors for treating of severe bone loss diseases | |
NO20074562L (en) | Procedures for the treatment of Parkinson's disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1841316 Country of ref document: EP |